MARKET

CRNX

CRNX

Crinetics Pharmaceuticals
NASDAQ
46.55
-0.84
-1.77%
After Hours: 46.55 0 0.00% 17:56 12/31 EST
OPEN
46.98
PREV CLOSE
47.39
HIGH
47.36
LOW
46.43
VOLUME
640.29K
TURNOVER
--
52 WEEK HIGH
53.55
52 WEEK LOW
24.10
MARKET CAP
4.42B
P/E (TTM)
-10.2696
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRNX last week (1222-1226)?
Weekly Report · 12/29/2025 09:06
Crinetics Pharmaceuticals (CRNX): Assessing Valuation After a 36% Three-Month Share Price Rebound
Simply Wall St · 12/24/2025 02:34
Weekly Report: what happened at CRNX last week (1215-1219)?
Weekly Report · 12/22/2025 09:06
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Reuters · 12/18/2025 21:05
Crinetics drops 9% after executive Dana Pizzuti steps down
TipRanks · 12/18/2025 17:25
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
Barchart · 12/18/2025 15:05
Evercore ISI Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
TipRanks · 12/18/2025 11:56
Crinetics Pharmaceuticals Grants $577,000 Severance and Bonus Eligibility to Departing Chief Medical Officer
Reuters · 12/17/2025 22:00
More
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

Webull offers Crinetics Pharmaceuticals Inc stock information, including NASDAQ: CRNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRNX stock methods without spending real money on the virtual paper trading platform.